Compare GSM & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | GHRS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United Kingdom | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.0M | 892.0M |
| IPO Year | N/A | 2021 |
| Metric | GSM | GHRS |
|---|---|---|
| Price | $4.67 | $12.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.3M | 235.2K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,373,244,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.97 | $6.72 |
| 52 Week High | $5.74 | $20.50 |
| Indicator | GSM | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 42.27 |
| Support Level | $4.39 | $12.04 |
| Resistance Level | $4.77 | $13.15 |
| Average True Range (ATR) | 0.18 | 0.86 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 68.75 | 24.35 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.